Login Register Cart 0
Systematic Review Article

新型前列腺癌诊断生物标志物：一个更新

卷 26, 期 6, 2019

页: [1045 - 1058] 页: 14

弟呕挨: 10.2174/0929867325666180914115416

价格: $65

摘要

目的：近年来，已有几种替代标准前列腺特异性抗原（PSA）用于前列腺癌（PCa）诊断的生物标记物。本系统评价的目的是评估目前关于替代血清和尿液生物标志物的诊断PCa的知识。 材料和方法：Medline进行了一项研究，仅限于2014年12月至2018年6月期间发表的英文文章，目的是更新先前发表的关于PCa生物标记的系列文章。系统评价和荟萃分析（PRISMA）标准的首选报告项目用于选择偏倚风险最低的研究。 结果：血清和尿液替代生物标志物对PCa诊断，分期和预后评估的标准PSA的新兴作用和实际争议，如前列腺健康指数（PHI），PCA3，ConfirmMDx，异常PSA糖基化，MiPS，miRNA等都在目前的审查。 结论：尽管不同的国际指南推荐或质疑了几种生物标志物的使用，但仍需要更大的前瞻性随机研究来验证其在PCa检测，鉴别，预后和治疗有效性方面的疗效。迄今为止，只有PHI和4K评分显示出区分更具攻击性的PCa的临床意义。此外，仍然需要基于与PCa风险分层和定制治疗相关的分子特征的新分级分类。

关键词: 生物标志物，诊断，预后，前列腺癌，血清，尿液。

« Previous Next »
[1]
Kgatle, M.M.; Kalla, A.A.; Islam, M.M.; Sathekge, M.; Moorad, R. Prostate cancer: epigenetic alterations, risk factors, and therapy. Prostate Cancer, 2016, 2016, 5653862.
[2]
Hendriks, R.J.; van Oort, I.M.; Schalken, J.A. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostatic Dis., 2017, 20(1), 12-19.
[3]
Hatakeyama, S.; Yoneyama, T.; Tobisawa, Y.; Ohyama, C. Recent progress and perspectives on prostate cancer biomarkers. Int. J. Clin. Oncol., 2017, 22(2), 214-221.
[4]
Kretschmer, A.; Tilki, D. Biomarkers in prostate cancer - Current clinical utility and future perspectives. Crit. Rev. Oncol. Hematol., 2017, 120, 180-193.
[5]
Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med., 2009, 6(7), e1000100.
[6]
Abrate, A.; Lughezzani, G.; Gadda, G.M.; Lista, G.; Kinzikeeva, E.; Fossati, N.; Larcher, A.; Dell’Oglio, P.; Mistretta, F.; Buffi, N.; Guazzoni, G.; Lazzeri, M. Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature. Korean J. Urol., 2014, 55(7), 436-445.
[7]
Loeb, S.; Catalona, W.J. The Prostate Health Index: A new test for the detection of prostate cancer. Ther. Adv. Urol., 2014, 6(2), 74-77.
[8]
Le, B.V.; Griffin, C.R.; Loeb, S.; Carvalhal, G.F.; Kan, D.; Baumann, N.A.; Catalona, W.J. [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J. Urol., 2010, 183(4), 1355-1359.
[9]
Wang, W.; Wang, M.; Wang, L.; Adams, T.S.; Tian, Y.; Xu, J. Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis. Sci. Rep., 2014, 4, 5012.
[10]
Fossati, N.; Buffi, N.M.; Haese, A.; Stephan, C.; Larcher, A.; McNicholas, T.; de la Taille, A.; Freschi, M.; Lughezzani, G.; Abrate, A.; Bini, V.; Palou Redorta, J.; Graefen, M.; Guazzoni, G.; Lazzeri, M. Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study. Eur. Urol., 2015, 68(1), 132-138.
[11]
Heidegger, I.; Klocker, H.; Steiner, E.; Skradski, V.; Ladurner, M.; Pichler, R.; Schäfer, G.; Horninger, W.; Bektic, J. [-2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer Prostatic Dis., 2014, 17(1), 70-74.
[12]
Eminaga, O.; Bögemann, M.; Breil, B.; Titze, U.; Wötzel, F.; Eltze, E.; Bettendorf, O.; Semjonow, A. Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy. Urol. Oncol., 2014, 32(8), 1317-1326.
[13]
Lazzeri, M.; Abrate, A.; Lughezzani, G.; Gadda, G.M.; Freschi, M.; Mistretta, F.; Lista, G.; Fossati, N.; Larcher, A.; Kinzikeeva, E.; Buffi, N.; Dell’Acqua, V.; Bini, V.; Montorsi, F.; Guazzoni, G. Relationship of chronic histologic prostatic inflammation in biopsy specimens with serum isoform [-2]proPSA (p2PSA), %p2PSA, and prostate health index in men with a total prostate-specific antigen of 4-10 ng/ml and normal digital rectal examination. Urology, 2014, 83(3), 606-612.
[14]
Tosoian, J.J.; Loeb, S.; Feng, Z.; Isharwal, S.; Landis, P.; Elliot, D.J.; Veltri, R.; Epstein, J.I.; Partin, A.W.; Carter, H.B.; Trock, B.; Sokoll, L.J. Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J. Urol., 2012, 188(4), 1131-1136.
[15]
Graham, J.; Kirkbride, P.; Cann, K.; Hasler, E.; Prettyjohns, M. Prostate cancer: summary of updated NICE guidance. BMJ, 2014, 348, f7524.
[16]
Russo, G.I.; Regis, F.; Castelli, T.; Favilla, V.; Privitera, S.; Giardina, R.; Cimino, S.; Morgia, G. A systematic review and meta-analysis of the diagnostic accuracy of prostate health index and 4-kallikrein panel score in predicting overall and highgrade prostate cancer. Clin. Genitourin. Cancer, 2017, 15(4), 429-439.e1.
[17]
Tosoian, J.J.; Druskin, S.C.; Andreas, D.; Mullane, P.; Chappidi, M.; Joo, S.; Ghabili, K.; Mamawala, M.; Agostino, J.; Carter, H.B.; Partin, A.W.; Sokoll, L.J.; Ross, A.E. Prostate Health Index density improves detection of clinically significant prostate cancer. BJU Int., 2017, 120(6), 793-798.
[18]
Gnanapragasam, V.J.; Burling, K.; George, A.; Stearn, S.; Warren, A.; Barrett, T.; Koo, B.; Gallagher, F.A.; Doble, A.; Kastner, C.; Parker, R.A. The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population. Sci. Rep., 2016, 6, 35364.
[19]
Mottet, N.; Bellmunt, J.; Bolla, M.; Briers, E.; Cumberbatch, M.G.; De Santis, M.; Fossati, N.; Gross, T.; Henry, A.M.; Joniau, S.; Lam, T.B.; Mason, M.D.; Matveev, V.B.; Moldovan, P.C.; van den Bergh, R.C.N.; Van den Broeck, T.; van der Poel, H.G.; van der Kwast, T.H.; Rouvière, O.; Schoots, I.G.; Wiegel, T.; Cornford, P. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur. Urol., 2017, 71(4), 618-629.
[20]
Daly, M.B.; Pilarsky, R.; Berry, M.; Buys, S.; Farmer, M.; Friedman, M.; Garber, J.E. NCCN Guidlines insight: genetic/familial high risk assessment: breast and ovarian, version 2. 2017. J. Natl. Compr. Canc. Netw., 2017, 15(1), 9-20.
[21]
Sanda, M.G.; Cadeddu, J.A.; Kirkby, E. Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. Part I: Risk stratification, shared decision making, and care options. J. Urol., 2017, 5347(17), 78003-2.
[22]
Sanda, M.G.; Cadeddu, J.A.; Kirkby, E.; Chen, R.C.; Crispino, T.; Fontanarosa, J.; Freedland, S.J.; Greene, K.; Klotz, L.H.; Makarov, D.V.; Nelson, J.B.; Rodrigues, G.; Sandler, H.M.; Taplin, M.E.; Treadwell, J.R. Clinically localized prostate cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended approaches and details of specific care Options. J. Urol., 2018, 199(4), 990-997.
[23]
McDonald, M.L.; Parsons, J.K. 4-Kallikrein test and kallikrein markers in prostate cancer screening. Urol. Clin. North Am., 2016, 43(1), 39-46.
[24]
Kretschmer, A.; Tilki, D. Biomarkers in prostate cancer - Current clinical utility and future perspectives. Crit. Rev. Oncol. Hematol., 2017, 120, 180-193.
[25]
Vickers, A.J.; Cronin, A.M.; Roobol, M.J.; Savage, C.J.; Peltola, M.; Pettersson, K.; Scardino, P.T.; Schröder, F.H.; Lilja, H. A four-kallikrein panel predicts prostate cancer in men with recent screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin. Cancer Res., 2010, 16(12), 3232-3239.
[26]
Vickers, A.; Cronin, A.; Roobol, M.; Savage, C.; Peltola, M.; Pettersson, K.; Scardino, P.T.; Schröder, F.; Lilja, H. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: An independent replication. J. Clin. Oncol., 2010, 28(15), 2493-2498.
[27]
Vedder, M.M.; de Bekker-Grob, E.W.; Lilja, H.G.; Vickers, A.J.; van Leenders, G.J.; Steyerberg, E.W.; Roobol, M.J. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur. Urol., 2014, 66(6), 1109-1115.
[28]
Vickers, A.J.; Gupta, A.; Savage, C.J. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol. Biomarkers Prev., 2011, 20(2), 255-261.
[29]
Carlsson, S.; Maschino, A.; Schröder, F.; Bangma, C.; Steyerberg, E.W.; van der Kwast, T.; van Leenders, G.; Vickers, A.; Lilja, H.; Roobol, M.J. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. Eur. Urol., 2013, 64(5), 693-699.
[30]
Voigt, J.D.; Zappala, S.M.; Vaughan, E.D.; Wein, A.J. The Kallikrein Panel for prostate cancer screening: Its economic impact. Prostate, 2014, 74(3), 250-259.
[31]
Dall’Olio, F.; Trinchera, M. Epigenetic Bases of Aberrant Glycosylation in Cancer. Int. J. Mol. Sci., 2017, 18(5), E998.
[32]
Kang, J.G.; Ko, J.H.; Kim, Y.S. Application of cancer-associated glycoforms and glycan-binding probes to an in vitro diagnostic multivariate index assay for precise diagnoses of cancer. Proteomics, 2016, 16(24), 3062-3072.
[33]
Drake, R.R.; Jones, E.E.; Powers, T.W.; Nyalwidhe, J.O. Altered glycosylation in prostate cancer. Adv. Cancer Res., 2015, 126, 345-382.
[34]
Yoneyama, T.; Ohyama, C.; Hatakeyama, S.; Narita, S.; Habuchi, T.; Koie, T.; Mori, K.; Hidari, K.I.; Yamaguchi, M.; Suzuki, T.; Tobisawa, Y. Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. Biochem. Biophys. Res. Commun., 2014, 448(4), 390-396.
[35]
Ishibashi, Y.; Tobisawa, Y.; Hatakeyama, S.; Ohashi, T.; Tanaka, M.; Narita, S.; Koie, T.; Habuchi, T.; Nishimura, S.; Ohyama, C.; Yoneyama, T. Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer. Prostate, 2014, 74(15), 1521-1529.
[36]
Ishikawa, T.; Yoneyama, T.; Tobisawa, Y.; Hatakeyama, S.; Kurosawa, T.; Nakamura, K.; Narita, S.; Mitsuzuka, K.; Duivenvoorden, W.; Pinthus, J.H.; Hashimoto, Y.; Koie, T.; Habuchi, T.; Arai, Y.; Ohyama, C. An automated micro-total immunoassay system for measuring cancer-associated α2,3-linked sialyl N-glycan-carrying prostate-specific antigen may improve the accuracy of prostate cancer diagnosis. Int. J. Mol. Sci., 2017, 18(2), E470.
[37]
Kojima, Y.; Yoneyama, T.; Hatakeyama, S.; Mikami, J.; Sato, T.; Mori, K.; Hashimoto, Y.; Koie, T.; Ohyama, C.; Fukuda, M.; Tobisawa, Y. Detection of core2 β-1,6-N-acetylglucosaminyltransferase in post-digital rectal examination urine is a reliable indicator for extracapsular extension of prostate cancer. PLoS One, 2015, 10(9), e0138520.
[38]
Hessels, D.; Klein Gunnewiek, J.M.; van Oort, I.; Karthaus, H.F.; van Leenders, G.J.; van Balken, B.; Kiemeney, L.A.; Witjes, J.A.; Schalken, J.A. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol., 2003, 44(1), 8-15.
[39]
Ferreira, L.B.; Palumbo, A.; de Mello, K.D.; Sternberg, C.; Caetano, M.S.; de Oliveira, F.L.; Neves, A.F.; Nasciutti, L.E.; Goulart, L.R.; Gimba, E.R. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer, 2012, 12, 507.
[40]
Shappell, S.B.; Fulmer, J.; Arguello, D.; Wright, B.S.; Oppenheimer, J.R.; Putzi, M.J. PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology, 2009, 73(2), 363-368.
[41]
Marks, L.S.; Fradet, Y.; Deras, I.L.; Blase, A.; Mathis, J.; Aubin, S.M.; Cancio, A.T.; Desaulniers, M.; Ellis, W.J.; Rittenhouse, H.; Groskopf, J. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology, 2007, 69(3), 532-535.
[42]
Aubin, S.M.; Reid, J.; Sarno, M.J.; Blase, A.; Aussie, J.; Rittenhouse, H.; Rittmaster, R.; Andriole, G.L.; Groskopf, J. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: Validation in the placebo arm of the dutasteride REDUCE trial. J. Urol., 2010, 184(5), 1947-1952.
[43]
Ankerst, D.P.; Groskopf, J.; Day, J.R.; Blase, A.; Rittenhouse, H.; Pollock, B.H.; Tangen, C.; Parekh, D.; Leach, R.J.; Thompson, I. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J. Urol., 2008, 180(4), 1303-1308.
[44]
van Gils, M.P.; Hessels, D.; Peelen, W.P.; Vergunst, H.; Mulders, P.F.; Schalken, J.A. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: A randomized, open-label, parallel-group pilot study. Prostate, 2009, 69(15), 1624-1634.
[45]
Bradley, A.L.; Glenn, E.P.; Gutman, S.; Samson, D.; Aronson, N. Comparative effectiveness review: Prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J. Urol., 2013, 190(2), 389-398.
[46]
Auprich, M.; Bjartell, A.; Chun, F.K.; de la Taille, A.; Freedland, S.J.; Haese, A.; Schalken, J.; Stenzl, A.; Tombal, B.; van der Poel, H. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur. Urol., 2011, 60(5), 1045-1054.
[47]
Chun, F.K.; de la Taille, A.; van Poppel, H.; Marberger, M.; Stenzl, A.; Mulders, P.F.; Huland, H.; Abbou, C.C.; Stillebroer, A.B.; van Gils, M.P.; Schalken, J.A.; Fradet, Y.; Marks, L.S.; Ellis, W.; Partin, A.W.; Haese, A. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur. Urol., 2009, 56(4), 659-667.
[48]
Auprich, M.; Haese, A.; Walz, J.; Pummer, K.; de la Taille, A.; Graefen, M.; de Reijke, T.; Fisch, M.; Kil, P.; Gontero, P.; Irani, J.; Chun, F.K. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur. Urol., 2010, 58(5), 727-732.
[49]
Hessels, D.; van Gils, M.P.; van Hooij, O.; Jannink, S.A.; Witjes, J.A.; Verhaegh, G.W.; Schalken, J.A. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate, 2010, 70(1), 10-16.
[50]
van Gils, M.P.; Hessels, D.; Hulsbergen-van de Kaa, C.A.; Witjes, J.A.; Jansen, C.F.; Mulders, P.F.; Rittenhouse, H.G.; Schalken, J.A. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate, 2008, 68(11), 1215-1222.
[51]
Auprich, M.; Chun, F.K.; Ward, J.F.; Pummer, K.; Babaian, R.; Augustin, H.; Luger, F.; Gutschi, S.; Budäus, L.; Fisch, M.; Huland, H.; Graefen, M.; Haese, A. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur. Urol., 2011, 59(1), 96-105.
[52]
Popa, I.; Fradet, Y.; Beaudry, G.; Hovington, H.; Beaudry, G.; Têtu, B. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod. Pathol., 2007, 20(11), 1121-1127.
[53]
Haese, A.; de la Taille, A.; van Poppel, H.; Marberger, M.; Stenzl, A.; Mulders, P.F.; Huland, H.; Abbou, C.C.; Remzi, M.; Tinzl, M.; Feyerabend, S.; Stillebroer, A.B.; van Gils, M.P.; Schalken, J.A. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur. Urol., 2008, 54(5), 1081-1088.
[54]
Loeb, S.; Bruinsma, S.M.; Nicholson, J.; Briganti, A.; Pickles, T.; Kakehi, Y.; Carlsson, S.V.; Roobol, M.J. Active surveillance for prostate cancer: A systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur. Urol., 2015, 67(4), 619-626.
[55]
Phillips, R. Prostate cancer: Improving early detection--can PCA3 do more? Nat. Rev. Urol., 2015, 12(1), 1.
[56]
Leyten, G.H.; Hessels, D.; Jannink, S.A.; Smit, F.P.; de Jong, H.; Cornel, E.B.; de Reijke, T.M.; Vergunst, H.; Kil, P.; Knipscheer, B.C.; van Oort, I.M.; Mulders, P.F.; Hulsbergen-van de Kaa, C.A.; Schalken, J.A. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur. Urol., 2014, 65(3), 534-542.
[57]
Wei, J.T.; Feng, Z.; Partin, A.W.; Brown, E.; Thompson, I.; Sokoll, L.; Chan, D.W.; Lotan, Y.; Kibel, A.S.; Busby, J.E.; Bidair, M.; Lin, D.W.; Taneja, S.S.; Viterbo, R.; Joon, A.Y.; Dahlgren, J.; Kagan, J.; Srivastava, S.; Sanda, M.G. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J. Clin. Oncol., 2014, 32(36), 4066-4072.
[58]
Gittelman, M.C.; Hertzman, B.; Bailen, J.; Williams, T.; Koziol, I.; Henderson, R.J.; Efros, M.; Bidair, M.; Ward, J.F. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: A prospective multicenter clinical study. J. Urol., 2013, 190(1), 64-69.
[59]
Cui, Y.; Cao, W.; Li, Q.; Shen, H.; Liu, C.; Deng, J.; Xu, J.; Shao, Q. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci. Rep., 2016, 6, 25776.
[60]
Tomlins, S.A. Urine PCA3 and TMPRSS2: ERG using cancer-specific markers to detect cancer. Eur. Urol., 2014, 65(3), 543-545.
[61]
Laxman, B.; Morris, D.S.; Yu, J.; Siddiqui, J.; Cao, J.; Mehra, R.; Lonigro, R.J.; Tsodikov, A.; Wei, J.T.; Tomlins, S.A.; Chinnaiyan, A.M. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res., 2008, 68(3), 645-649.
[62]
Sanguedolce, F.; Cormio, A.; Brunelli, M.; D’Amuri, A.; Carrieri, G.; Bufo, P.; Cormio, L. Urine TMPRSS2: ERG fusion transcript as a biomarker for prostate cancer: Literature review. Clin. Genitourin. Cancer, 2016, 14(2), 117-121.
[63]
Tomlins, S.A.; Day, J.R.; Lonigro, R.J.; Hovelson, D.H.; Siddiqui, J.; Kunju, L.P.; Dunn, R.L.; Meyer, S.; Hodge, P.; Groskopf, J.; Wei, J.T.; Chinnaiyan, A.M. Urine TMPRSS2: ERG plus pca3 for individualized prostate cancer risk assessment. Eur. Urol., 2016, 70(1), 45-53.
[64]
Yao, Y.; Wang, H.; Li, B.; Tang, Y. Evaluation of the TMPRSS2: ERG fusion for the detection of prostate cancer: A systematic review and meta-analysis. Tumour Biol., 2014, 35(3), 2157-2166.
[65]
Partin, A.W.; Van Neste, L.; Klein, E.A.; Marks, L.S.; Gee, J.R.; Troyer, D.A.; Rieger-Christ, K.; Jones, J.S.; Magi-Galluzzi, C.; Mangold, L.A.; Trock, B.J.; Lance, R.S.; Bigley, J.W.; Van Criekinge, W.; Epstein, J.I. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J. Urol., 2014, 192(4), 1081-1087.
[66]
Loeb, S.; Dani, H. Whom to Biopsy: Prediagnostic risk stratification with biomarkers, nomograms, and risk calculators. Urol. Clin. North Am., 2017, 44(4), 517-524.
[67]
Hessels, D.; Schalken, J.A. Urinary biomarkers for prostate cancer: A review. Asian J. Androl., 2013, 15(3), 333-339.
[68]
Lee, W.H.; Morton, R.A.; Epstein, J.I.; Brooks, J.D.; Campbell, P.A.; Bova, G.S.; Hsieh, W.S.; Isaacs, W.B.; Nelson, W.G. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA, 1994, 91(24), 11733-11737.
[69]
Goessl, C.; Müller, M.; Heicappell, R.; Krause, H.; Straub, B.; Schrader, M.; Miller, K. DNA-based detection of prostate cancer in urine after prostatic massage. Urology, 2001, 58(3), 335-338.
[70]
Wojno, K.J.; Costa, F.J.; Cornell, R.J.; Small, J.D.; Pasin, E.; Van Criekinge, W.; Bigley, J.W.; Van Neste, L. reduced rate of repeated prostate biopsies observed in confirmmdx clinical utility field study. Am. Health Drug Benefits, 2014, 7(3), 129-134.
[71]
Stewart, G.D.; Van Neste, L.; Delvenne, P.; Delrée, P.; Delga, A.; McNeill, S.A.; O’Donnell, M.; Clark, J.; Van Criekinge, W.; Bigley, J.; Harrison, D.J. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: Results of the MATLOC study. J. Urol., 2013, 189(3), 1110-1116.
[72]
Waterhouse, R.L., Jr; Van Neste, L.; Moses, K.A.; Barnswell, C.; Silberstein, J.L.; Jalkut, M.; Tutrone, R.; Sylora, J.; Anglade, R.; Murdock, M.; Shiffman, Z.; Vandenberg, T.; Shah, N.; Carter, M.; Krispin, M.; Groskopf, J.; Van Criekinge, W. Evaluation of an epigenetic assay for predicting repeat prostate biopsy outcome in african american men.. Urology., , 2018. S0090-4295(18), 30315-30317.
[73]
Cucchiara, V.; Cooperberg, M.R.; Dall’Era, M.; Lin, D.W.; Montorsi, F.; Schalken, J.A.; Evans, C.P. Genomic markers in prostate cancer decision making. Eur. Urol., 2018, 73(4), 572-582.
[74]
Bertoli, G.; Cava, C.; Castiglioni, I. MicroRNAs as biomarkers for diagnosis, prognosis and theranostics in prostate cancer. Int. J. Mol. Sci., 2016, 17(3), 421.
[75]
Shukla, K.K.; Misra, S.; Pareek, P.; Mishra, V.; Singhal, B.; Sharma, P. Recent scenario of microRNA as diagnostic and prognostic biomarkers of prostate cancer. Urol. Oncol., 2017, 35(3), 92-101.
[76]
Fabris, L.; Ceder, Y.; Chinnaiyan, A.M.; Jenster, G.W.; Sorensen, K.D.; Tomlins, S.; Visakorpi, T.; Calin, G.A. The potential of microRNAs as prostate cancer biomarkers. Eur. Urol., 2016, 70(2), 312-322.
[77]
Kanwal, R.; Plaga, A.R.; Liu, X.; Shukla, G.C.; Gupta, S. MicroRNAs in prostate cancer: Functional role as biomarkers. Cancer Lett., 2017, 407, 9-20.
[78]
Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O’Briant, K.C.; Allen, A.; Lin, D.W.; Urban, N.; Drescher, C.W.; Knudsen, B.S.; Stirewalt, D.L.; Gentleman, R.; Vessella, R.L.; Nelson, P.S.; Martin, D.B.; Tewari, M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA, 2008, 105(30), 10513-10518.
[79]
Cheng, H.H.; Mitchell, P.S.; Kroh, E.M.; Dowell, A.E.; Chéry, L.; Siddiqui, J.; Nelson, P.S.; Vessella, R.L.; Knudsen, B.S.; Chinnaiyan, A.M.; Pienta, K.J.; Morrissey, C.; Tewari, M. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One, 2013, 8(7), e69239.
[80]
Gonzales, J.C.; Fink, L.M.; Goodman, O.B., Jr; Symanowski, J.T.; Vogelzang, N.J.; Ward, D.C. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin. Genitourin. Cancer, 2011, 9(1), 39-45.
[81]
Brase, J.C.; Johannes, M.; Schlomm, T.; Fälth, M.; Haese, A.; Steuber, T.; Beissbarth, T.; Kuner, R.; Sültmann, H. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer, 2011, 128(3), 608-616.
[82]
Guo, K.; Liang, Z.; Li, F.; Wang, H. Comparison of miRNA and gene expression profiles between metastatic and primary prostate cancer. Oncol. Lett., 2017, 14(5), 6085-6090.
[83]
Zhang, Z.; Lanz, R.B.; Xiao, L.; Wang, L.; Hartig, S.M.; Ittmann, M.M.; Feng, Q.; He, B. The tumor suppressive miR-200b subfamily is an ERG target gene in human prostate tumors. Oncotarget, 2016, 7(25), 37993-38003.
[84]
Shen, J.; Hruby, G.W.; McKiernan, J.M.; Gurvich, I.; Lipsky, M.J.; Benson, M.C.; Santella, R.M. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate, 2012, 72(13), 1469-1477.
[85]
Mahn, R.; Heukamp, L.C.; Rogenhofer, S.; von Ruecker, A. Müller, SC Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology, 2011, 77(5), e9-e16.
[86]
Zheng, Q.; Peskoe, S.B.; Ribas, J.; Rafiqi, F.; Kudrolli, T.; Meeker, A.K.; De Marzo, A.M.; Platz, E.A.; Lupold, S.E. Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy. Prostate, 2014, 74(16), 1655-1662.
[87]
Moltzahn, F.; Olshen, A.B.; Baehner, L.; Peek, A.; Fong, L.; Stöppler, H.; Simko, J.; Hilton, J.F.; Carroll, P.; Blelloch, R. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res., 2011, 71(2), 550-560.
[88]
Valentino, A.; Calarco, A.; Di Salle, A.; Finicelli, M.; Crispi, S.; Calogero, R.A.; Riccardo, F.; Sciarra, A.; Gentilucci, A.; Galderisi, U.; Margarucci, S.; Peluso, G. Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: Molecular basis and pathophysiological consequences. Oncogene, 2017, 36(43), 6030-6040.
[89]
Porkka, K.P.; Pfeiffer, M.J.; Waltering, K.K.; Vessella, R.L.; Tammela, T.L.; Visakorpi, T. MicroRNA expression profiling in prostate cancer. Cancer Res., 2007, 67(13), 6130-6135.
[90]
Porkka, K.P.; Ogg, E.L.; Saramäki, O.R.; Vessella, R.L.; Pukkila, H.; Lähdesmäki, H.; van Weerden, W.M.; Wolf, M.; Kallioniemi, O.P.; Jenster, G.; Visakorpi, T. The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers. Genes Chromosomes Cancer, 2011, 50(7), 499-509.
[91]
Tong, A.W.; Fulgham, P.; Jay, C.; Chen, P.; Khalil, I.; Liu, S.; Senzer, N.; Eklund, A.C.; Han, J.; Nemunaitis, J. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther., 2009, 16(3), 206-216.
[92]
Schaefer, A.; Jung, M.; Mollenkopf, H.J.; Wagner, I.; Stephan, C.; Jentzmik, F.; Miller, K.; Lein, M.; Kristiansen, G.; Jung, K. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer, 2010, 126(5), 1166-1176.
[93]
Leite, K.R.; Tomiyama, A.; Reis, S.T.; Sousa-Canavez, J.M.; Sañudo, A.; Camara-Lopes, L.H.; Srougi, M. MicroRNA expression profiles in the progression of prostate cancer--from high-grade prostate intraepithelial neoplasia to metastasis. Urol. Oncol., 2013, 31(6), 796-801.
[94]
Kang, S.G.; Ha, Y.R.; Kim, S.J.; Kang, S.H.; Park, H.S.; Lee, J.G.; Cheon, J.; Kim, C.H. Do microRNA 96, 145 and 221 expressions really aid in the prognosis of prostate carcinoma? Asian J. Androl., 2012, 14(5), 752-757.
[95]
Volinia, S.; Calin, G.A.; Liu, C.G.; Ambs, S.; Cimmino, A.; Petrocca, F.; Visone, R.; Iorio, M.; Roldo, C.; Ferracin, M.; Prueitt, R.L.; Yanaihara, N.; Lanza, G.; Scarpa, A.; Vecchione, A.; Negrini, M.; Harris, C.C.; Croce, C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. USA, 2006, 103(7), 2257-2261.
[96]
Ambs, S.; Prueitt, R.L.; Yi, M.; Hudson, R.S.; Howe, T.M.; Petrocca, F.; Wallace, T.A.; Liu, C.G.; Volinia, S.; Calin, G.A.; Yfantis, H.G.; Stephens, R.M.; Croce, C.M. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res., 2008, 68(15), 6162-6170.
[97]
Gasparrini, S.; Cimadamore, A.; Mazzucchelli, R.; Scarpelli, M.; Massari, F.; Raspollini, M.R.; Galosi, A.B.; Lopez-Beltran, A.; Cheng, L.; Montironi, R. Pathology and molecular updates in tumors of the prostate: Towards a personalized approach. Expert Rev. Mol. Diagn., 2017, 17(8), 781-789.
[98]
Tanase, C.P.; Codrici, E.; Popescu, I.D.; Mihai, S.; Enciu, A.M.; Necula, L.G.; Preda, A.; Ismail, G.; Albulescu, R. Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery. Oncotarget, 2017, 8(11), 18497-18512.
[99]
Lamy, P.J.; Allory, Y.; Gauchez, A.S.; Asselain, B.; Beuzeboc, P.; de Cremoux, P.; Fontugne, J.; Georges, A.; Hennequin, C.; Lehmann-Che, J.; Massard, C.; Millet, I.; Murez, T.; Schlageter, M.H.; Rouvière, O.; Kassab-Chahmi, D.; Rozet, F.; Descotes, J.L.; Rébillard, X. Prognostic biomarkers used for localised prostate cancer management: A systematic review. Eur. Urol. Focus, 2017, 4(6), 790-803.

Rights & Permissions Print Cite
Article Metrics
94
10
1
1
© 2024 Bentham Science Publishers | Privacy Policy